Home › Trial NCT07829900
First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer
- Trial IDNCT07829900
- StatusCompleted
- PhaseN/A
- Study typeObservational
- SponsorXin Li
- Enrollment2250
- Start date2020-04-20
- ConditionsHER2-Positive Breast Cancer · Advanced Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.